Skip to main content
Clinical Trials/NCT03418844
NCT03418844Active, not recruitingNot Applicable

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Centre Francois Baclesse38 sites in 1 country268 target enrollmentStarted: May 7, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
268
Locations
38
Primary Endpoint
The late sequelae of chemotherapy, particularly cardiovascular and pulmonary disorders, in adult patients in remission of a rare cancer of the ovary treated by surgery, supplemented or not by chemotherapy.

Study Overview

Brief Summary

While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remission of rare ovarian cancer remain poorly explored.

The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Age> 18 years;
  • •Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;
  • •Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group);
  • •Patient in remission more than 2 years after the end of the initial treatment;
  • •Relapse authorized if remission more than 2 years after the end of the treatment;
  • •Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix);
  • •Patient having signed his consent to participate

Exclusion Criteria

  • •Pregnant or breastfeeding woman;
  • •Psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results;
  • •Person deprived of liberty;
  • •Major subject to a legal protection measure or unable to express his consent.

Arms & Interventions

Interest group (patients treated with chemotherapy)

Other

Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Intervention: Self-questionnaires of living conditions and quality of life (Other)

Interest group (patients treated with chemotherapy)

Other

Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Intervention: Cardiac, pulmonary, auditory and biological assessment (Diagnostic Test)

Patient control group (patients not treated with chemotherapy)

Other

Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Intervention: Self-questionnaires of living conditions and quality of life (Other)

Patient control group (patients not treated with chemotherapy)

Other

Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment

Intervention: Cardiac, pulmonary, auditory and biological assessment (Diagnostic Test)

Healthy volunteers

Other

Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.

Intervention: Self-questionnaires of living conditions and quality of life (Other)

Outcomes

Primary Outcomes

The late sequelae of chemotherapy, particularly cardiovascular and pulmonary disorders, in adult patients in remission of a rare cancer of the ovary treated by surgery, supplemented or not by chemotherapy.

Time Frame: 2 years after surgery

The chronic fatigue by questionnaires

Time Frame: 2 years after surgery

The quality of life by questionnaires

Time Frame: 2 years after surgery

Secondary Outcomes

  • The fertility monitoring by questionnaires(2 years after surgery)
  • The parental projects by age (≤ 45 years) by questionnaires(2 years after surgery)
  • The symptoms of menopause by questionnaires(2 years after surgery)
  • Theimpact of cancer and its treatments on the trajectory and professional situation by questionnaires(access to work, professional ambition, financial situation ...);(2 years after surgery)

Investigators

Sponsor
Centre Francois Baclesse
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (38)

Loading locations...

Similar Trials